Home
About Us
Pipeline
Partnerships
Investors
News & Events
Careers
| S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values |
| Clinical Trials | Technologies & Capabilities |
| News & Press Releases | Participation in Events | Publications |
| Join Our Team | Career Opportunities |
 |
 |
|
Every great advance in science has issued from a new audacity of imagination. John Dewey |
|
|
|
Partnerships S*BIO translates a profound understanding of cancer biology into best-in-class clinical compounds, establishing us as a preferred partner and collaborator in the development of innovative cancer treatments. S*BIO therefore seeks partnerships with both commercial and scientific organizations to expand the clinical development and marketing options for our product candidates. Working with these partners should improve the chances of rapid approval for our compounds as well as help to reduce their time to market. We seek partners who are able to actively participate in the clinical development and future plans for our compounds by adding value to our research and development or commercialization capabilities. We would aim to retain ownership of our compounds, whilst creating equitable licensing, co-development and co-promotional partnerships. In addition, we are interested in collaboration opportunities to exploit non-oncology opportunities for our compounds. For partnering information, please contact partner@sbio.com Current partnerships Onyx Pharmaceuticals, Inc In January 2009 S*BIO entered into a development collaboration and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize our novel JAK2 inhibitors, SB1518 and SB1578. S*BIO will perform all the clinical development activities for SB1518 and preclinical to clinical development activities for SB1578 during the option period. Onyx can elect to exercise its exclusive options for SB1518 and SB1578 at certain predetermined stages of development for each product separately and independently. Each option converts into an exclusive license for development and commercialization rights for SB1518 and SB1578 in all indications in the United States, Canada and Europe where Onyx will assume all of the associated development costs. S*BIO retains rights to develop and commercialize SB1518 and SB1578 in the rest of the world. The development of SB1518 will initially focus on the treatment of myelofibrosis and other myeloproliferative diseases. JAK2 inhibitors are implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases. For more information on the collaboration, please see the press release Tragara Pharmaceuticals, Inc In January 2009 S*BIO announced a development collaboration with Tragara Pharmaceuticals, Inc., granting Tragara a worldwide exclusive license to develop and commercialize our novel multi-kinase inhibitor SB1317. S*BIO will perform certain preclinical activities under the agreement; Tragara is responsible for all IND enabling, development and commercialization activities. SB1317 development will be initially focused on the treatment of hematologic malignancies and Tragara will also explore the therapeutic potential of the compound’s activity in solid tumors.. For more information on the collaboration, please see the press release
|
